Novel screening test for celiac disease using peptide functionalised gold nanoparticles

Abstract

AIMTo develop a screening test for celiac disease based on the coating of gold nanoparticles with a peptide sequence derived from gliadin, the protein that triggers celiac disease.METHODS20 nm gold nanoparticles were first coated with NeutrAvidin. A long chain Polyethylene glycol (PEG) linker containing Maleimide at the Ω-end and Biotin group at the α-end was used to ensure peptide coating to the gold nanoparticles. The maleimide group with the thiol (-SH) side chain reacted with the cysteine amino acid in the peptide sequence and the biotinylated and PEGylated peptide was added to the NeutrAvidin coated gold nanoparticles. The peptide coated gold nanoparticles were then converted into a serological assay. We used the peptide functionalised gold nanoparticle-based assay on thirty patient serum samples in a blinded assessment and compared our results with the previously run serological and pathological tests on these patients.RESULTSA stable colloidal suspension of peptide coated gold nanoparticles was obtained without any aggregation. An absorbance peak shift as well as color change was caused by the aggregation of gold nanoparticles following the addition of anti-gliadin antibody to peptide coated nanoparticles at levels associated with celiac disease. The developed assay has been shown to detect anti-gliadin antibody not only in quantitatively spiked samples but also in a small-scale study on real non-hemolytic celiac disease patient’s samples.CONCLUSIONThe study demonstrates the potential of gold nanoparticle-peptide based approach to be adapted for developing a screening assay for celiac disease diagnosis. The assay could be a part of an exclusion based diagnostic strategy and prove particularly useful for testing high celiac disease risk populations.

Engineering precision nanoparticles for drug delivery

“…The unique property of graphene oxide, which binds low amounts of albumin, allows strong adsorption of proteins that are present in the plasma at low levels 62 . Other studies use magnetic NPs 63 or AuNPs 64 , 65 , which are simple to use, in biomarker detection assays, thereby saving time and money if compared with existing methods that require substantial sample processing. In addition to diagnostic screening, some therapeutic applications of NPs aim to remodel the tumour microenvironment to promote particle accumulation and penetration, and thus increase drug efficacy, and/or to sensitize tumours to a particular therapy 66 – 68 .…”

Gold Nanoparticles: Multifaceted Roles in the Management of Autoimmune Disorders

“…The sensor’s sensitivity was about 1297.1 pg, and a detection limit was found at 0.1 fg per 6 µL. In another study, Kaur et al [ 266 ] developed a screening test based on the 20 nm GNPs functionalized with a sequence of the gliadin-derived peptide, which triggers the CD. They demonstrated that this functionalized GNP with a novel peptide-based assay is helpful for pre-selecting CD, especially in high-risk pediatric populations confirmed by mucosal biopsy.…”

Emerging Biomarkers for Screening and Management of Celiac Disease

“…A deamidated peptide sequence is derived from α -gliadin amino acids that detects the immunogenic peptide sequence acting as a trigger for CeD [ 37 ]. The AuNP peptide assay seems promising for development as a POCT as it is based on the formation of a precipitate, and there occurs a reduction in color of a positive sample in the presence of a CeD-specific autoantibody, with an overall accuracy of 86.6% [ 38 ].…”